MPH Fundamental Analysis - MEDICURE INC

Fundamental Rating

Overall MPH gets a fundamental rating of 3 out of 10. We evaluated MPH against 23 industry peers in the Biotechnology industry. The financial health of MPH is average, but there are quite some concerns on its profitability. MPH has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

MPH had negative earnings in the past year.

MPH had a positive operating cash flow in the past year.

MPH had negative earnings in 4 of the past 5 years.

MPH had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

MPH has a Return On Assets of -12.83%. This is amongst the best in the industry. MPH outperforms 82.61% of its industry peers.

Looking at the Return On Equity, with a value of -19.81%, MPH belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-12.83%
ROE	-19.81%
ROIC	N/A

ROA(3y)-0.74%

ROA(5y)-4.98%

ROE(3y)-1.05%

ROE(5y)-8.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 47.67%, MPH belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.

In the last couple of years the Gross Margin of MPH has remained more or less at the same level.

MPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	47.67%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y-1.35%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MPH does not have a ROIC to compare to the WACC, probably because it is not profitable.

MPH has about the same amout of shares outstanding than it did 1 year ago.

MPH has less shares outstanding than it did 5 years ago.

MPH has a worse debt/assets ratio than last year.

2.2 Solvency

MPH has an Altman-Z score of -2.13. This is a bad value and indicates that MPH is not financially healthy and even has some risk of bankruptcy.

MPH's Altman-Z score of -2.13 is fine compared to the rest of the industry. MPH outperforms 60.87% of its industry peers.

The Debt to FCF ratio of MPH is 0.79, which is an excellent value as it means it would take MPH, only 0.79 years of fcf income to pay off all of its debts.

MPH has a better Debt to FCF ratio (0.79) than 100.00% of its industry peers.

MPH has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of MPH (0.03) is better than 78.26% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	0.79
Altman-Z	-2.13

ROIC/WACCN/A

WACC7.58%

2.3 Liquidity

MPH has a Current Ratio of 1.44. This is a normal value and indicates that MPH is financially healthy and should not expect problems in meeting its short term obligations.

MPH's Current ratio of 1.44 is fine compared to the rest of the industry. MPH outperforms 60.87% of its industry peers.

MPH has a Quick Ratio of 1.00. This is a normal value and indicates that MPH is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.00, MPH perfoms like the industry average, outperforming 56.52% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.44
Quick Ratio	1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MPH have decreased strongly by -68.69% in the last year.

Looking at the last year, MPH shows a very strong growth in Revenue. The Revenue has grown by 24.30%.

Measured over the past years, MPH shows a small growth in Revenue. The Revenue has been growing by 1.66% on average per year.

EPS 1Y (TTM)-68.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-279.68%

Revenue 1Y (TTM)24.3%

Revenue growth 3Y0.25%

Revenue growth 5Y1.66%

Sales Q2Q%56.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MPH. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of MPH indicates a rather cheap valuation: MPH is cheaper than 100.00% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	9.38
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MPH!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDICURE INC

TSX-V:MPH (12/31/2025, 7:00:00 PM)

1.14

-0.11 (-8.8%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-19 2025-11-19/amc

Earnings (Next)04-27 2026-04-27

Inst Owners23.1%

Inst Owner ChangeN/A

Ins Owners26.42%

Ins Owner ChangeN/A

Market Cap11.90M

Revenue(TTM)26.21M

Net Income(TTM)-3.43M

Analysts40

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.45
P/FCF	9.38
P/OCF	6.93
P/B	0.69
P/tB	2.61
EV/EBITDA	N/A

EPS(TTM)-0.33

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.12

FCFY10.66%

OCF(TTM)0.16

OCFY14.43%

SpS2.51

BVpS1.66

TBVpS0.44

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.83%
ROE	-19.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	47.67%
FCFM	4.84%

ROA(3y)-0.74%

ROA(5y)-4.98%

ROE(3y)-1.05%

ROE(5y)-8.57%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y-1.35%

F-Score4

Asset Turnover0.98

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	0.79
Debt/EBITDA	N/A
Cap/Depr	17.23%
Cap/Sales	1.71%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.44
Quick Ratio	1
Altman-Z	-2.13

F-Score4

WACC7.58%

ROIC/WACCN/A

Cap/Depr(3y)19.82%

Cap/Depr(5y)17.11%

Cap/Sales(3y)1.99%

Cap/Sales(5y)1.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-68.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-279.68%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)24.3%

Revenue growth 3Y0.25%

Revenue growth 5Y1.66%

Sales Q2Q%56.6%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y17.48%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-13.56%

FCF growth 3Y-41.4%

FCF growth 5YN/A

OCF growth 1Y4%

OCF growth 3Y-29.85%

OCF growth 5YN/A

MEDICURE INC / MPH.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICURE INC?

ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA.

What is the valuation status for MPH stock?

ChartMill assigns a valuation rating of 2 / 10 to MEDICURE INC (MPH.CA). This can be considered as Overvalued.

What is the profitability of MPH stock?

MEDICURE INC (MPH.CA) has a profitability rating of 3 / 10.

MEDICURE INC (MPH.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDICURE INC / MPH.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICURE INC?

What is the valuation status for MPH stock?

What is the profitability of MPH stock?